It makes little sense given $.50 to $.54 2011 guidance. Right now, this stock should be at least $12.50, with a high of $16 in 3 months if earnings come in on the high end.
My guess is that this will be at $12.50 within a week or two, and then trading in a range of $12.50-$14 until the next earnings release.
It seems that this stock doesn't get a lot of attention (as is evident by the lack of postings here), even though it's a solid business headed by a CEO who really knows this business and has an effective strategy.
>>Anyone understand why we're sitting here at $11?<<
I think it is due to the guidance for the current quarter. Expectations of 8 to 10 cents in eps, is not what I, and maybe a lot of other folks and institutions, wanted to hear. It is a great company with a great product that may be a true money maker for the company. Unfortunately, you have hemostat products that are flat to down and they make a significant portion of the revenues. The eps guidance means that we have to wait an additional three months to hear the next results. If the eps turn out to be as mediocre as the last quarter's, then it would be a waste of time and investment. Hence, people may be waiting to see eps being exceeded not just met.